Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24053122 | 0.89 | KDM4E (0.34) | KDM4EMAPK1HIF1ASMN1; SMN2HSD17B10 | |
| SCHEMBL21151855 | 0.83 | ACACB (0.33) | KDM4EMAPK1HIF1ASMN1; SMN2HSD17B10 | |
| SCHEMBL13290414 | 0.82 | KDM4E (0.40) | KDM4EMAPK1HIF1ASMN1; SMN2HSD17B10 | |
| SCHEMBL21915798 | 0.81 | PAOX (0.38) | KDM4EMAPK1HIF1ASMN1; SMN2HSD17B10 | |
| SCHEMBL6729276 | 0.80 | SMN1; SMN2 (0.38) | KDM4ESMN1; SMN2HSD17B10TSHRALDH1A1 | |
| SCHEMBL6729273 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10TSHREPHX1LMNA | |
| SCHEMBL13290400 | 0.80 | KDM4E (0.39) | KDM4EMAPK1HIF1ASMN1; SMN2HSD17B10 | |
| SCHEMBL21452807 | 0.78 | SMN1; SMN2 (0.41) | KDM4EMAPK1HIF1ASMN1; SMN2HSD17B10 | |
| SCHEMBL21477756 | 0.78 | KDM4E (0.37) | KDM4EMAPK1HIF1ASMN1; SMN2HSD17B10 | |
| SCHEMBL13463180 | 0.78 | KDM4E (0.43) | KDM4EMAPK1HIF1ASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4186888-A1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220411410-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-12-29 | — | — | US | disclosed |
| WO-2022246266-A1 | BASE EDITING OF TRANSTHYRETIN GENE | BEAM THERAPEUTICS INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2021155267-A2 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | MODERNATX, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021076805-A1 | MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | Moderna TX, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021026358-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2021-02-11 | — | — | WO | disclosed |
| WO-2020227537-A1 | DIFFERENTIALLY EXPRESSED IMMUNE CELL MICRORNAS FOR REGULATION OF PROTEIN EXPRESSION | Modernatx, Inc (US) | 2020-11-12 | — | — | WO | disclosed |
| EP-3712162-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| WO-2020061367-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20190314291-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. | 2019-10-17 | — | — | US | disclosed |
| US-8461128-B2 | Anti-microbial agents and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110071206-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100331344-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-30 | — | — | US | disclosed |
| US-7776905-B2 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| EP-0777658-B1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AG (DE) | 1999-12-15 | — | — | EP | disclosed |
| US-5885934-A | HERBICIDES OR FOR THE DESICCATION/DEFOLIATION OF PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-03-23 | — | — | US | disclosed |
| EP-0777658-A1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996005179-A1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411410-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4235/4885MAPK1 4563/4885HIF1A 1715/4885 |
| US-20110071206-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | KDM4E 4235/4885MAPK1 4563/4885HIF1A 1715/4885 |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | KDM4E 4235/4885MAPK1 4563/4885HIF1A 1715/4885 |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | CFTR, ABCD3, ABCC2 | KDM4E 2724/4885MAPK1 4083/4885HIF1A 318/4885 |
| US-20190314291-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | LCP2, CD14, MYD88 | KDM4E 4100/4885MAPK1 2801/4885HIF1A 2944/4885 |
| US-20100331344-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | KDM4E 4235/4885MAPK1 4563/4885HIF1A 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.